Longitudinal Trends in Major Cardiovascular Risk Factors in the Czech Population;Dlouhodobé Trendy Hlavních Rizikových Faktorů Kardiovaskulárních Onemocnění v České Populaci

Casopis Lekaru Ceskych

Volumn 143, Issue 4, 2004, Pages 219-226

  Cífková, Renata ^a   Skodova Z ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Blood pressure; BMI; Cardiovascular disease; Cross sectional surveys; Hypertension; Population random sample; Smoking; Total cholesterol

Indexed keywords

CHOLESTEROL;

ADULT; ARTICLE; AWARENESS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CZECH REPUBLIC; DIASTOLIC BLOOD PRESSURE; FATALITY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MALE; MORBIDITY; MORTALITY; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SMOKING;

EID: 17144438995     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Zemřelí 2002, ÚZIS, ČR, 2003.
2. Uemura, K., Píša, Z.: Trends in cardiovascular disease mortality in industrialized countries since 1950. Wld. Hlth. Statist. Quart., 1988, 41, s.155-178.
3. European cardiovascular disease statistics. British Heart Foundation, February 2000, London.
4. WHO MONICA Project Principal Investigators: The World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular disease): A major international collaboration. J. Clin. Epidemiol., 1988, 41, s. 105-114.
5. Tunstall-Pedoe, H., Kuulasma, K., Mähönen, M. et al.: for the WHO MONICA (Monitoring trends and determinants in cardiovascular disease) Project: Contribution of trends in survial and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet, 1999, 353, s. 1547-1557.
6. Kannel, W. B., McGee, D. L., Gordon, T.: A general cardiovascular risk profile: The Framingham Study. Am. J. Cardiol., 1976, 74, s. 46-51.
7. Anderson, K. M., Wilson, P. W. F., Odell, P. M., Kannel, W. B.: An updated coronary risk profile, A statement for health professionals. Circulation, 1991, 83, s. 356-62.
8. Pyörala, K., De Backer, G., Graham, I. et al.: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J., 1994, 15, s. 130-31.
9. Wood, D., De Backer, G., Faergeman, O. et al.: Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur. Heart J., 1998, 19, s. 1434-1503.
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 02-5215. Circulation, 2002, 106, s. 3143-3420.
11. De Backer, G., Ambrosioni, E., Borch-Johnsen, K. et al.: Third Joint Task Force of European and other societies on cardiovacular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J., 2003, 24, s. 1601 až 1610.
12. Grundy, S. M., Pasternak, R., Greenland, P. et al.: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation, 1999, 100, s. 1481-1492.
13. Heller, R. F., Chinn, S., Pedoem, H.D., Rose, G.: How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. BMJ, 1984, 288, s. 1409-1411.
14. Wald, N. J., Law, M., Watt, H. C. et al.: Apolipoproteins and ischaemic heart disease implications for screening. Lancet, 1994, 343, s. 75-79.
15. Píša, Z., Škodová, Z., Cícha, Z. et al.: Krevní tlak a kontrola hypertenze v populaci ČSR. Prakt. Lék., 1989, 69, s. 213-216.
16. Bobák, M., Škodová, Z., Píša, Z.: Vztah mezi vzděláním a prevalencí kardiovaskulárních rizikových faktorů. Čas. Lék. čes., 1994, 133, s. 627-632.
17. Rosolová, H., Krejsová, L., Emmer, J. et al.: Vliv věku a vzdělání na rizikový profil mužů a žen v průmyslové populaci. Vnitř. Lék., 1991, 37, s. 678-85.
18. Kuulasmaa, K., Tunstall-Pedoe, H., Dobson, A. et al.: for the WHO MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet, 2000, 355, s. 675-687.
19. Després, J. P.: The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients risk. Obes. Res., 1998, 6 (Suppl. 1), s. 8S-17S.
20. Bjorntorp, P.: Body fat distribution, insulin resistance, and metabolic diseases. Nutrition, 1997, 13, s. 795-803.
21. Seidell, J. C.: Time trends in obesity: An epidemiological perspective. Horm. Metab. Res., 1997, 29, s. 155-158.
22. Seidell, J. C.: Obesity in Europe: scaling an epidemic. Int. J. Obes., 1995, 19, s. S1-S4.
23. Flegal, K. M., Caroll, M. D., Kuczmarski, R. J., Johnson. C. L.: Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J. of Obes., 1998, 22, s. 39-47.
24. Williamson, D. F., Madans, J., Anda, R. F. et al.: Smoking cessation and severity of weight gain in a national cohort. N. Engl. J. Med., 1991, 324, s. 739-745.
25. Boyle, C. A., Dobson, A. J., Egger, C., Magnus, P.: Can the increasing weight of Australians be explained by the decreasing prevalence of cigarette smoking? Int. J. Obes., 1994, 18, s. 55-60.
26. Krauss, R. M., Winston, M., for Fletcher, B. J., Grundy, S. M. (conference codirectors): Obesity Impact on Cardiovascular Disease. Circulation, 1998, 98, s. 1472-1476.
27. Eckel, R.H.: Obesity and heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation, 1997, 96, s. 3248-3250.
28. Dengel, D. R., Galeckim, A. T., Hagberg, J. M., Pratley, R. E.: The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am. J. Hypertens., 1998, 11, s. 1405-1412.
29. Howard, G., Wagenknecht, L. E., Burke, G. L. et al.: Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA, 1998, 279, s. 119-124.
30. Lopez, A. D., Collishaw, N. E., Piha, T.: A descriptive model of the cigarette epidemic in developed countries. Tobacco Control, 1994, 3, s. 242-247.
31. Molarius, A., Parson, R. W., Dobson, A. J. et al.: Trends in cigarette smoking in 36 population from the early 1980s to the mid-1990s: Findings from the WHO MONICA project. Am. J. Public. Health, 2001, 91, s. 206-212.
32. Elliott, P., Stamler, J., Nichols, R. et al.: for the Intersalt Cooperative Research Group. et al.: Intersalt revisited: further analyses of 24-hour sodium excretion and blood pressure within and across populations. BMJ, 1996, s. 312, 1249-1253.
33. Law, M. R., Frost, C. D., Wald, N. J.: By how much does dietary salt reduction lower blood pressure? Analysis of data from trials of salt reduction. BMJ, 1991, 302, s. 819-824.
34. Culter, J. A., Follmann, D., Alender, P. S.: Randomized trials of sodium reduction: an overview. Am. J. Clin. Nutr., 1997, s. 65, 643S až 651S.
35. Midgley, J. P., Matthev, A. G., Greenwood, C. M. T., Logan, A. G.: Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA, 1996, 275, s. 1590-1597.
36. Sacks, F. M. et al.: for the DASH-sodium collaborative research group. N. Eng. J. Med., 2001, 344, s. 3-10.
37. Puddey, I. B., Beilin, L. J., Rakic, V.: Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol., 1997, 2, s. 159-170.
38. Sekavová, H.: Vývoj spotřeby potravin v domácnostech od roku 1989. Výživa, 1999, 54, s. 69-71.
39. Burt, V. J., Cutler, J. A., Higgins, M. et al.: Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population: data from the health examination surveys: 1960-1991. Hypertension, 1995, 26, s. 60-69.
40. Erdine, S.: How well is hypertension controlled in Europe? J. Hypertens., 2000, 18, s. 1348-1350.
41. Marques-Vidal, P., Tuomilehto, J.: Hypertension, awarness, treatment and control in the community: is the rule of halves still valid. J. Hum. Hypertens., 1997, 11, s. 213-220.
42. Joffres, M. R. et al.: Awarness, treatment and control of hypertension in Canada. Am. J. Hypertens., 1997, 10, s. 1097-1102.
43. Hansson, L. et al.: on behalf of the HOT Study Group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351, s. 1755-1762.
44. Mancia, G., Grassi, G.: Systolic and diastolic blood pressure control in antihypertensive drug trials. J. Hypertens., 2002, 20, s. 1461-1464.
45. Rose, G.: The strategy of prevention. Lessons from cardio-vascular disease. Brit. Med. J., 1981, 282, s. 1847-1851.
46. Vartiainen, E., Puska, P., Pekkanen, J. et al.: Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. Brit. Med. J., 1994, 309, s. 23-27.
47. Puska, P.: The North Karelia Project: From community intervention to national activity in lowering cholesterol levels and CHD risk. Eur. Heart J., 1999, 20, s. S9-S13.